Zoetis Inc. $ZTS Shares Sold by NewEdge Wealth LLC

NewEdge Wealth LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 50.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,174 shares of the company’s stock after selling 15,310 shares during the period. NewEdge Wealth LLC’s holdings in Zoetis were worth $2,220,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Forum Financial Management LP increased its holdings in shares of Zoetis by 4.2% in the 2nd quarter. Forum Financial Management LP now owns 3,662 shares of the company’s stock valued at $571,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on ZTS shares. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Finally, Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Up 1.1%

ZTS stock opened at $128.73 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company’s 50 day simple moving average is $125.41 and its 200-day simple moving average is $134.72. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The firm has a market capitalization of $54.34 billion, a PE ratio of 21.38, a P/E/G ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.